MedTrace Logo

Screening of Cancer Through Novel Female Specific Biomarkers

NCT03951428 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2019-05-15

No results posted yet for this study

Summary

Can reliable biomarkers be identified for detection of cancer at early stages using menstrual blood (MB)? Preliminary mass spectrometry (MS) results suggest that MB provides biomarkers for identification of disease such as cancers.

Conditions

Interventions

DIAGNOSTIC_TEST

Menstrual Blood Screening Test

The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.

Sponsors & Collaborators

  • Baylor Scott and White Health

    collaborator OTHER

  • LifeStory Health Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2019-11-01
Completion
2019-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03951428 on ClinicalTrials.gov